

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				SERIAL NO.		To be assigned	
				FILING DATE		Concurrently herewith	
				APPLICANT		Michael Tolar MARTIN	
				GROUP		To be assigned	
				EXAMINER		To be assigned	
				ATTORNEY DOCKET NO.		PU4975USW	

  

U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
MP	1.	3,828,078	08/06/1974	MROZIK			

Continue on page \_\_\_\_\_

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
MP	2.	WO 01/17982	03/15/2001	PCT			

Continue on page \_\_\_\_\_

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)	
MP	3. Balzarini, "Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy," <i>Biochemical Pharmacology</i> 58(1):1-27 (Jun. 1999).
MP	4. De Clercq, "Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection," <i>Il Famaco</i> 54:26-45 (1999).

Continue on page \_\_\_\_\_

EXAMINER	DATE CONSIDERED
a. Paul	9/16/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.